Physician profile
Idan Sharon
NPI 1205852845
$2,098,209.61
in general payments reported to CMS, 2019-2025
46 companies · $439K in 2025
The $439K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225K · 2020: $189K · 2021: $289K · 2022: $339K · 2023: $299K · 2024: $318K · 2025: $439K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $799K · Honoraria: $120K · Food and Beverage: $57K · Consulting Fee: $40K · Travel and Lodging: $36K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,000 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $799,266.93 |
| Honoraria | $119,525.00 |
| Food and Beverage | $56,865.43 |
| Consulting Fee | $40,358.75 |
| Travel and Lodging | $36,179.03 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,000.00 |
| Education | $378.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $411,383.62 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $324,548.09 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Sk Life Science, INC. | $217,028.41 | 2020-2025 | Xcopri |
| Otsuka America Pharmaceutical, INC. | $194,122.68 | 2019-2025 | Rexulti, Nuedexta |
| Amgen INC. | $168,957.98 | 2019-2023 | Aimovig |
| Alkermes, INC. | $139,589.80 | 2021-2025 | Lybalvi, Aristada |
| Eisai INC. | $95,461.32 | 2019-2025 | |
| Axsome Therapeutics, INC. | $92,217.19 | 2023-2025 | Auvelity, Symbravo |
| Vanda Pharmaceuticals INC. | $77,669.43 | 2024-2025 | Fanapt, Hetlioz |
| Allergan, INC. | $59,068.45 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $54,829.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $54,704.50 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49,252.97 | 2022-2025 | Caplyta |
| Biohaven Pharmaceuticals, INC. | $43,503.58 | 2020-2021 | |
| Neurelis, INC. | $34,116.80 | 2022-2025 | Valtoco |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20,779.36 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $20,235.41 | 2019-2022 | |
| Almatica Pharma LLC | $18,058.52 | 2021-2024 | Loreev Xr, Gralise |
| Pfizer INC. | $8,890.66 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $5,130.92 | 2023-2024 | Aptiom |
| Bausch Health US, LLC | $1,769.26 | 2019-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $1,543.53 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $1,439.09 | 2019-2025 | Qelbree, Qelbree, Oxtellar Xr |
| Currax Pharmaceuticals LLC | $1,072.01 | 2021-2023 | Contrave, Onzetra Xsail |
| Lundbeck LLC | $945.56 | 2020-2025 | Rexulti, Brintellix, Abilify Maintena |
| Corium, LLC | $346.60 | 2022-2024 | Adlarity, Azstarys |
| Horizon Therapeutics Plc | $270.32 | 2019 | |
| Lilly USA, LLC | $214.21 | 2021-2023 | Reyvow, Emgality |
| Scilex Pharmaceuticals INC. | $200.40 | 2021-2025 | Ztlido |
| Novartis Pharmaceuticals Corporation | $169.33 | 2019-2021 | |
| Assertio Therapeutics, INC. | $102.52 | 2019 | |
| Novo Nordisk INC | $92.94 | 2019-2022 | |
| Genzyme Corporation | $74.85 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $66.29 | 2022-2025 | Spravato |
| Aimmune Therapeutics, INC. | $62.37 | 2024-2025 | Zenpep |
| Ironshore Pharmaceuticals INC. | $57.29 | 2019 | |
| Neos Therapeutics, LP | $47.03 | 2019-2023 | Adzenys Xr-Odt |
| Arbor Pharmaceuticals, INC. | $45.45 | 2019-2020 | |
| Impel Pharmaceuticals INC. | $23.94 | 2022 | |
| Avanir Pharmaceuticals, INC. | $20.22 | 2019 | |
| Zyla Life Sciences, INC. | $19.46 | 2019 | |
| Acorda Therapeutics, INC | $18.83 | 2023 | Inbrija |
| Neurocrine Biosciences, INC. | $17.49 | 2021 | |
| Merck Sharp & Dohme LLC | $14.56 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.33 | 2023 | Seglentis |
| Biogen, INC. | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Idan Sharon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.